CAL
CRSP icon

Capital Analysts LLC’s CRISPR Therapeutics CRSP Stock Holding History

Capital Analysts LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Hold
49
– – ﹤0.01% 1449
2025
Q4 		$3K Hold
49
– – ﹤0.01% 1381
2025
Q3 		$3K Hold
49
– – ﹤0.01% 1346
2025
Q2 		$2K Hold
49
– – ﹤0.01% 1316
2025
Q1 		$2K Hold
49
– – ﹤0.01% 1303
2024
Q4 		$2K Hold
49
– – ﹤0.01% 1217
2024
Q3 		$2K Hold
49
– – ﹤0.01% 1208
2024
Q2 		$3K Hold
49
– – ﹤0.01% 1078
2024
Q1 		$3K Buy
+49
New +$3.51K ﹤0.01% 1016

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Analysts LLC's CRSP Position: Q1 2026 in Review

Capital Analysts LLC held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 49 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1449.

Capital Analysts LLC first reported a position in CRSP in Q1 2024 and has held it in 9 quarters since. The position peaked at $3K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Capital Analysts LLC held 49 shares of CRISPR Therapeutics worth $2K as of Q1 2026.
  • Capital Analysts LLC left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #1449 holding.
  • Capital Analysts LLC first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Capital Analysts LLC's CRISPR Therapeutics position peaked at $3K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.